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Abstract
UDPS combined with genotypic algorithms for prediction of HIV-1 co-receptor usage may provide quantitative data about the tropism
of each variant present in the viral quasispecies. The aim of the present study was to assess co-receptor usage by ultra-deep pyrose-
quencing (UDPS), in comparison with the reference phenotypic test (Trofile ), in patients who are candidates for CCR5 antagonist
treatment, in both circulating and proviral HIV-1. Seventeen patients who were tested by Trofile were enrolled. UDPS of the V3 loop
region was carried out on both plasma RNA and proviral DNA. Genotypic prediction of co-receptor usage was established by position-
specific score matrices (PSSM) and confirmed, in discordant cases, with geno2pheno. Genetic heterogeneity of the RNA and DNA
quasispecies was assessed as well. A total of 196 729 V3 sequences were considered (mean coverage per site, 6346). Concordance
between phenotypic test and UDPS with PSSM was 0.82. Geno2pheno results were in line with those obtained with PSSM. Proviral
quasispecies were more heterogeneous than those found in circulating HIV. In most patients eligible for CCR5 antagonist treatment,
X4 variants were detected in proviral DNA, ranging from 1.0% to 52.7%. UDPS combined with genotypic algorithms for co-receptor
usage prediction highlighted the presence of minority variants, with a discordant tropism with respect to the predominant population,
in both circulating viral and proviral HIV. In most patients treated with Maraviroc the virological response was independent of the pres-
ence of X4 in proviral DNA. The clinical impact of minority X4 variants present in patients who are candidates for anti-CCR5 antago-
nists remains a crucial point to be addressed.
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Introduction
Accurate prediction of HIV co-receptor usage and tropism is
essential to establish patient eligibility for treatment with
co-receptor antagonists [1–3].
Phenotypic assays, such as Trofile [4,5], are the most fre-
quently used at present, and are mostly applied to genomes
from circulating virions, while proviral DNA sequences pres-
ent in the cellular reservoirs are usually not investigated.
Genotypic methods for predicting co-receptor usage, that
are cheaper and faster than phenotypic tests, are based on
the highly variable viral glycoprotein (gp)120 V3 loop region,
which is the main determinant of HIV tropism [6–9]. Gener-
ally, sequence-based methods provide information only on
the predominant circulating variants, while HIV-1 is present
in each individual as a swarm of highly related variants
referred to as quasispecies. Ultra-deep pyrosequencing
(UDPS) is a potent tool to analyse HIV quasispecies, showing
that proviral DNA present in peripheral blood mononuclear
cells (PBMC) may be more heterogeneous than circulating
viral RNA, and may hide segregated variants [10,11].
The aim of the present study was to assess co-receptor
usage by UDPS, combined with genotypic algorithms for tro-
pism prediction, in comparison with the reference phenotypic
test, in patients who are candidates for CCR5 antagonist treat-
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ment. Quasispecies of RNA from circulating virions were com-
pared with those of proviral DNA in PBMC, in terms of both
co-receptor usage and genetic heterogeneity.
Materials and Methods
Patients and phenotypic test
A cross-sectional analysis of 17 patients infected with sub-
type B HIV-1, candidates for CCR5 antagonist treatment,
was performed (adults, median age 40 years, range 29–60,
46% male). Four patients were diagnosed with HIV-1 infec-
tion in the last 2 years and were naive for antiretroviral
treatment (patients 10, 11, 12 and 17); the remaining 13
patients had a median history of HIV-1 infection of 15 years
(range 13–22 years) and had received several successive lines
of highly active antiretroviral therapy (HAART), which had
failed. Phenotypic and genotypic analyses were performed
before the assignment to a new therapeutic regimen, possibly
containing Maraviroc (MVC). At this time, all patients had
detectable viral loads, with a mean HIV-RNA of 4.3 log cp/
mL (SD, ±0.9 log cp/mL) and a mean CD4 cell count of 294/
mmc (SD, ±174 cells/mmc).
The study was approved by the institutional ethics com-
mittee, and the patients agreed to participate by signing an
informed consent.
As a phenotypic test, two versions (standard and enhanced)
of the Trofile assay (Monogram Biosciences, San Francisco,
CA, USA) have been used throughout this study, according to
their availability at the time of sampling [4]. On the basis of
Trofile results, a sub-group of five patients (patients 1, 2, 5, 8
and 10) started MVC treatment, in the context of optimized
background therapy (OBT). Mean follow-up period was
20.75 ± 1.89 (ES) weeks. The genotypic sensitivity score (GSS)
of these patients was 3 for patients 1 and 5, and 2 for patients
2, 8 and 10. Of these, four showed a durable response, while
patient 5 showed viral rebound after an initial response.
Ultra-deep pyrosequencing
Total DNA extraction from PBMC was performed using a
DNA blood kit (Qiagen, Hilden, Germany). Plasma HIV-1
RNA was extracted using the QIAamp Viral RNA kit
(Qiagen). The number of templates actually undergoing
UDPS analysis was evaluated by a commercial real time PCR
(Abbott real time HIV, Abbott Molecular Inc., Abbott Park,
IL, USA) for plasma samples, and by a quantitative real-time
PCR targeting the LTR region for PBMC DNA [12].
V3-specific RT-PCR was performed as described [10].
Unique in-house-designed stretches of eight nucleotides
(multiplex identifiers, MIDs) were used to tag each sample.
To maximize the genetic heterogeneity to be amplified and
sequenced, for each sample the amplicons from at least four
replicate PCR reactions were pooled, representing, for viral
RNA, the content of 1 mL of plasma, and, for DNA, the
content of 2–6·106 PBMC. UDPS was carried out with the
454 Life Sciences platform (GS-FLX, Roche Applied Science,
Monza, Italy) as described in [10].
Correction pipeline and UDPS error rate estimation
A correction pipeline based on the translation of the
sequences and conservation of only the coding ones was
adopted as previously described [10].
To estimate the UDPS error rate, a plasmid clone con-
taining the region of interest was sequenced in parallel with
the Sanger method [10]. Any nucleotide differences between
the two methods were considered to be GS-FLX sequencing
errors. Within the env region, the crude error rate was
0.43%, reduced to 0.058% after the application of the correc-
tion pipeline (0.043% for non-homopolymeric regions and
0.11% for homopolymeric regions). Based on these data, and
taking into account the estimated error rate for the high
fidelity polymerase used to obtain the amplicons (approxi-
mately 1 · 10)6 mutations/bp/duplication [13]), frequencies
of variants exceeding by at least five times the corrected
error rate were considered to reflect true variability and not
procedural/experimental errors, according to Vandenbroucke
et al. [14]. Considering the number of viral templates actually
undergoing UDPS and the corrected error rate, the thresh-
old of sensitivity was set to 0.3%, corresponding to at least
six corrected sequences/sample. In addition, although the
adopted correction pipeline was expected to withdraw the
defective sequences harbouring hypermutations, the possibil-
ity that this phenomenon could contribute to enhance the
heterogeneity of proviral DNA quasispecies was considered.
To calculate the probability of G to A hypermutation, for
each sample the original nucleotide reads were grouped into
consensus reads by the AVA software (Roche), and submitted
to the HyperMut 2.0 algorithm (http://www.hiv.lanl.gov/
content/sequence/HYPERMUT/hypermut.html).
Prediction of co-receptor usage by position-specific score
matrices (PSSM)
To obtain a score for co-receptor usage prediction, PSSM
analysis [8] was applied to each V3 amino acid sequence
obtained by UDPS, using the X4R5 matrix (http://www.
fortinbras.us/cgi-bin/fssm/fssm.pl). The 95th and 5th percen-
tiles for X4 and R5 tropism scores were higher than )2.88
and lower than )6.96, respectively. In addition to scores,
PSSM provides a binary prediction of the co-receptor usage:
1 predicts CXCR4 usage (either X4 or R5X4 phenotype)
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and 0 predicts CCR5 usage only (R5 phenotype). For each
HIV RNA sample, the UDPS coupled with PSSM results were
compared with the results of Trofile. For discordant results,
the genotypic predictor algorithm geno2pheno was also used
(http://www.geno2pheno.org), setting the false positive rate
(FPR) to 5% [15].
Calculation of heterogeneity parameters
The amino acid sequences resulting from the correction
pipeline were analysed to establish genetic heterogeneity of
viral quasispecies. Complexity was calculated using normal-
ized Shannon entropy as in Abbate et al. [16]. To assess
diversity, the mean genetic distance among amino acid
sequences was calculated using PROTDIST with the Jones–
Taylor–Thornton matrix, and the resulting distance matrices
were analysed with an in-house written code.
Statistical analysis
The concordance between UDPS + PSSM and trofile results
was established by calculating the Cohen’s Kappa index. The
Mann–Whitney non-parametric test was used to calculate
the statistical significance of the differences between hetero-
geneity parameters of RNA and DNA viral quasispecies.
Non-parametric Spearman rank correlation was used to eval-
uate the correlations between heterogeneity, viral/proviral
load and CD4.
Results
Comparison between conventional phenotypic tests and
UDPS in predicting co-receptor usage
UDPS analysis provided a total of 129 797 sequences. The
application of the correction pipeline yielded 92 229 edited
sequences (ranging from 742 to 9502 sequences/patient),
which were submitted to PSSM analysis. Overall, the number
of templates undergoing UDPS ranged from 750 to 250 000
for HIV RNA, and from 300 to 1500 for proviral DNA. By
this approach, considering an average of 5423 ± 2481 and
7459 ± 5085 analysed reads for HIV RNA and DNA, respec-
tively, the oversampling size ranged from 0.02 to 7.2 for
RNA and from 5.0 to 25 for proviral DNA.
The comparison between Trofile and PSSM in classifying
HIV tropism is shown in Table 1. Because the samples were
analysed with two different versions of Trofile (standard and
enhanced), depending on the version available at the moment
of testing, and because UDPS provides quantitative data, R5
classification by the two methods was considered concor-
dant if the frequency of CXCR4-using variants detected by
UDPS was lower than the sensitivity for X4 detection by
standard and enhanced Trofile (5% and 0.3%, respectively).
The frequencies of such variants obtained by UDPS are
reported in Table 2 (RNA samples). Overall concordance
between Trofile and UDPS plus classical PSSM was 0.82
(Cohen K index ± SE: 0.60 ± 0.24), with discordant results
in three cases: in two cases (patients 6 and 13) Trofile classi-
fication was D/M whereas UDPS classification was R5; in the
remaining case (patient 17), Trofile classification was R5, but
UDPS classification was D/M, due to the presence of 20.2%
of CXCR4-using RNA genome variants (Table 2).
To further characterize the discordant results between
Trofile and UDPS + PSSM, the sequences of these discordant
cases were re-evaluated by geno2pheno, indicating concor-
dant classification by UDPS + PSSM and UDPS + geno
2pheno, with a similar proportion of CXCR4-using variants
in all three cases (not shown).
Quasispecies comparison between circulating viral and
proviral HIV-1
UDPS was also used to establish the genetic heterogeneity
of V3 loop quasispecies of proviral DNA compared with cir-
culating virus. Paired plasma and PBMC samples were avail-
able for 14 of the 17 patients included in the study. The
total number of proviral V3 sequences yielded by UDPS was
164 426, reduced to 104 500 after correction (average 7464,
range 1467–21758 sequences/patient). Genetic complexity
and diversity are shown in Table 2.
An inverse correlation between diversity of circulating
virus and CD4 numbers was observed (r = )0.521,
TABLE 1. Comparison between phenotypic (Trofile) and
genotypic (UDPS plus PSSM) results for the prediction of
co-receptor usage and tropism
Patient ID Trofilea UDPSa (PSSM)
Pt1 R5 R5
Pt2 R5 R5
Pt3 D/M D/M
Pt4 D/M D/M
Pt5 R5 R5
Pt6 D/M R5
Pt7 D/M D/M
Pt8 R5 R5
Pt9 D/M D/M
Pt 10 R5b R5
Pt11 R5b R5
Pt 12 R5b R5
Pt 13 D/Mb R5
Pt 14 R5b R5
Pt 15 R5b R5
Pt 16 R5b R5
Pt 17 R5b D/M
aViral tropism is reported as R5, X4 or D/M by Trofile and as a binary classifica-
tion by PSSM: CXCR4-using virus (either X4 or R5X4 phenotype) or CCR5
usage only (R5 phenotype). The samples classified as CXCR4-using by PSSM are
reported as D/M in the table. UDPS results were classified as R5 if the fre-
quency of CXCR4-using variants was below the sensitivity for X4 + D/M detec-
tion of the Trofile test used for the same sample (5% and 0.3%, for standard
and enhanced Trofile, respectively).
bResults by enhanced Trofile.
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p 0.0032). Both complexity and diversity were significantly
higher in proviral HIV DNA with respect to circulating
viral RNA (median values of complexity, 0.2111 vs. 0.1432
p 0.0149; median values of diversity, 589.0 · 10)4 vs.
234.5 · 10)4 substitutions per site; p 0.023 in proviral and
circulating HIV, respectively). The evaluation of G to A
hypermutation in proviral DNA did not show statistically sig-
nificant values. No correlation between the viral or proviral
load values and the parameters of quasispecies heterogeneity
was observed.
Direct comparison between the relative abundance and
absolute concentration of CXCR4-using variants in circulat-
ing (RNA) and proviral (DNA) HIV quasispecies from each
patient is shown in Table 2. Most patients (9 out of 14, 64%)
harboured CXCR4-using variants in proviral DNA, at vari-
able frequencies (1.0–90.8%), leading to absolute concentra-
tion ranging between 2 and 2595 cp/106 PBMC, while these
variants were below the detection threshold in five patients
(patients 1, 11, 13, 14 and 16). Three out of the five patients
who were treated with MVC (patients 2, 5 and 8) displayed
detectable CXCR4-using variants in proviral DNA: in two
cases (patients 2 and 8, showing full response) the frequency
of these variants was >20% (absolute concentrations of 2594
and 89 cp/106 PBMC, respectively, Table 2), while the only
patient who experienced virological failure (patient 5) har-
boured 1% (corresponding to 2 cp/106 PBMC) CXCR4-using
variants in proviral DNA (Table 2).
Overall, the relative abundances of CXCR4-using variants
in circulating viral and proviral HIV-1 genomes were
positively correlated (Spearman correlation, r = 0.603,
P 0.023). However, at the single patient level, the pattern of
quasispecies composition in plasma and proviral genomes
was quite different in terms of co-receptor usage. PSSM
score distributions are shown in Fig. 1 for eight out of 11
patients classified as R5 by Trofile, for whom paired RNA
and DNA samples were available. In all these patients, viral
HIV quasispecies were uniformly distributed in the range of
score values for R5 tropism, while proviral quasispecies gen-
erally showed a bimodal distribution (rather than a continu-
ous spectrum) of the scores, suggesting the existence of a
mixed population created by distinct R5 and X4 variants,
with a frequency of X4 components that may account for up
TABLE 2. Comparison of V3 quasispecies present in circulating (RNA) and proviral (DNA) HIV-1 genomes
Patient ID
number
CD4+
(cells/lL)
Sample
type
No of
analysed
sequences Complexitya Diversityb
HIV RNA
(cp/mL)
HIV DNA
(cp/106 cells)
% of
CXCR4-using
variants
CXCR4-using
HIV RNA (cp/mL)
HIV DNA
(cp/106 cells)
1 449 RNA 8052 0.0802 61 20 837 <0.3 <63
DNA 7781 0.2067 426 126 <0.3 <1
2 315 RNA 6137 0.1075 78 86 560 <0.3 <260
DNA 13 037 0.2514 1880 4922 52.7 2594
3 31 RNA 4331 0.2067 359 146 789 89.4 131 229
DNA 6470 0.2106 306 6220 90.8 5648
4 322 RNA 9434 0.1687 353 181 262 8.6 15 589
DNA 6804 0.2177 610 220 15.9 35
5 445 RNA 7230 0.1764 263 470 289 <0.3 <1411
DNA 6980 0.2814 676 192 1.0 2
6 411 RNA 6966 0.0766 56 3655 <0.3 <11
DNA 8746 0.1980 1004 1042 15.3 159
7 457 RNA 7517 0.1389 314 3987 64.8 2584
DNA 6026 0.2496 503 50 66.2 33
8 265 RNA 9502 0.3028 859 11 186 0.3 34
DNA 8782 0.2394 1307 328 27.1 89
9 354 RNA 6509 0.1010 1123 4714 10.8 509
DNA 5919 0.1470 579 314 4.0 13
10 239 RNA 3101 0.2610 359 1529 <0.3 <5
DNA ND NA NA 204 NA NA
11 24 RNA 4425 0.2565 717 854 112 <0.3 <2562
DNA 21 757 0.3318 1086 180 <0.3 <1
12 15 RNA 3426 0.1575 486 503 352 <0.3 <1510
DNA ND NA NA 640 NA NA
13 454 RNA 3990 0.1537 206 8331 <0.3 <25
DNA 1908 0.2116 397 <227 <0.3 <1
14 39 RNA 4331 0.1072 90 19 532 <0.3 <59
DNA 2740 0.1096 82 224 <0.3 <1
15 537 RNA 3950 0.1474 171 9786 <0.3 <29
DNA 1467 0.1828 599 ND 7.7 NA
16 410 RNA 2550 0.0995 68 45 044 <0.3 <135
DNA 6015 0.1179 106 2134 <0.3 <6
17 238 RNA 742 0.3614 1525 144 000 20.2 29 088
DNA NDa NA NA 1504 NA NA
The patients who started MVC treatment are indicated in bold characters.
aNormalized Shannon entropy.
bMean number of substitutions ·10)4/per site, evaluated by PROTDIST, with the Jones–Taylor–Thornton evolutionary model.
ND, not done, insufficient sample.
NA, not applicable.
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to half of the whole population in proviral genomes (see also
Table 2).
Discussion
In the past, the concordance between HIV-1 tropism
inferred by the phenotypic test and bioinformatic tools has
been shown to be low in comparison with those obtained
using clonal sequences in clinical samples [17,18]. This was
probably due to the fact that the V3 loop is highly variable
and that the virus is present in an infected patient as a quasi-
species. As shown in the present study, UDPS coupled with
a genotypic algorithm for prediction of co-receptor usage
may represent a magnifying glass for a detailed description
of the viral quasispecies in terms of co-receptor usage. In
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FIG. 1. PSSM score distribution of HIV-1 variants associated with circulating and proviral quasispecies in patients eligible for treatment with
CCR5 antagonists. The PSSM score distributions of viral quasispecies present in the circulating viral RNA (R) and in the proviral DNA (D) in
eight out of 11 patients eligible for CCR5 antagonist treatment on the basis of Trofile results, with both circulating and archived genome data
available, are shown. Vertical lines indicate 95th and 5th percentiles for CXCR4 and CCR5 predicted co-receptor usage (> )2.88 and < )6.96,
respectively). The proportion of total CXCR4-using variants (either X4 or R5X4 phenotype) present in the quasispecies, as assessed by classical
PSSM, is indicated in each plot as %X4. Patients 1, 2, 5 and 8 underwent MVC treatment; patient 5 experienced virological failure.
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addition, UDPS may be used in samples where routine phe-
notype tests could not be employed, due to difficulties in
amplification of env, low fitness or low infectivity of the
recombinant virus [14]. In the present study, generally con-
cordant results were observed between UDPS plus PSSM
and Trofile for circulating virus. In addition, the results
obtained with a different algorithm (geno2pheno) were in
line with those obtained by PSSM, supporting the reliability
of the data.
One relevant aspect is that the presence of minority vari-
ants, with a discordant tropism with respect to the predomi-
nant viral population, may be highlighted by UDPS. The
clinical impact of minority X4 variants present in patients
who are candidates for anti-CCR5 antagonists at the time of
starting therapy is a matter of debate. It has been shown that
about half of the virological failures may be attributed to the
expansion of pre-existing low-level X4 variants [19], in the
presence of a positive selection force such as administration
of a CCR5 antagonist [20,21]. In previous studies UDPS
revealed that proviral DNA may hide segregated variants
[10,11].One widely recognized problem with this ultrasensi-
tive approach is the under- or oversampling of the viral
quasispecies pool, due to variable viral genome copy num-
bers of the starting material. Particularly, target resampling
due to a low copy number may lead to over-estimating the
frequency of some variants just for the stochastic nature of
the PCR amplification. However, in the present study the
number of samples with a low copy number was rather lim-
ited, and the lowest amount of templates undergoing UDPS
was 750 for HIV RNA and 300 for proviral DNA, in line
with other studies [14].
Taking into account the possible limitations due to the
uneven oversampling size, it appears that the proviral quasi-
speciesis is more heterogeneous than the circulating one.
This finding is not unexpected, as proviral sequences include
variants from different stages of infection, and not only those
that are involved in active replication, and is in agreement
with a recent study [22]. Although it is not possible to evalu-
ate how many proviral variants are actually replication com-
petent, we can assume that part of them may generate viral
progeny, as previously shown [11]. In this respect, it is possi-
ble that some DNA variants, possessing enhanced fitness in
a given environmental condition, may preferentially replicate,
leading to a selective expansion in the viral quasispecies
released in the plasma, which may partly account for lower
heterogeneity of RNA quasispecies.
In this study a high proportion of patients eligible for
CCR5 antagonist treatment (on the basis of Trofile) har-
boured X4 variants in the proviral genomes, and one dis-
played X4 variants also in the circulation, at a frequency of
20.2%. In particular, among the five patients who received
MVC, three harboured X4 variants in proviral DNA at vari-
able frequencies (1–52.7%), but only one (with 1% X4 vari-
ants in proviral DNA) developed virological failure. The
absolute number of X4 genomes harboured in proviral DNA
of this failing patient was lower than those detected in the
DNA of the two responding patients (Table 2).
On the whole, it is not possible to evaluate whether the
presence of X4 variants only in proviral DNA is irrelevant
with respect to MVC treatment, because effective OBT
could minimize the negative impact of these variants. On the
other hand, patients may benefit from CCR5 antagonist
treatment even in the presence of X4 variants, at least in
terms of CD4 increase [23–25]. In this respect, the discor-
dant classification by UDPS vs. Trofile, and the differences
between circulating and proviral compartments in the com-
position of viral quasispecies, observed for some patients in
the present study, may represent the key for the reappraisal
of this issue. Specific studies aimed at establishing X4 fre-
quency thresholds that can be tolerated in the presence of
CCR5 antagonist treatment and longitudinal evaluation of
patients not responding to CCR5 antagonists will help to
unravel the dynamics of resistant HIV variants surfacing dur-
ing treatment.
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